CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kiromic Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kiromic Biopharma Inc
7707 Fannin, Suite 140
Phone: (832) 968-4888p:832 968-4888 HOUSTON, TX  77054  United States Ticker: KRBPKRBP
Business Summary
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company. The Company is engaged in developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. It is using its proprietary DIAMOND artificial intelligence (AI) 2.0 platform to discover targets for immuno-oncology. It has five clinical programs to study its key product candidates: Deltacel-01, Isocel combination, Alexis-ISO-1, Procel combination, and Alexis-PRO-1. Deltacelis its first allogeneic, off-the-shelf GDT cell-based product in Phase 1 clinical-stage. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf CAR-GDT cells, and they are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs that target PD-L1. Isocel product candidate consists of engineered GDTs that target Mesothelin Isoform 2 positive tumors (Iso-Meso).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board MichaelNagel 61 1/27/2022 10/1/2020
Interim Chief Executive Officer, Director PietroBersani 55 1/1/2022 6/1/2020
Interim Chief Financial Officer and Principal Accounting BrianHungerford 48 6/1/2023 6/1/2023
3 additional Officers and Directors records available in full report.

Business Names
Business Name
GreenPlanet Pharma, Inc
InSilico Solutions
InSilico Solutions, LLC
KRBP

General Information
Number of Employees: 35 (As of 12/31/2023)
Outstanding Shares: 1,545,920 (As of 8/7/2024)
Shareholders: 82
Stock Exchange: OTC
Federal Tax Id: 464762913
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025